 Lamivudine
"Lamivudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
| Descriptor ID |
D019259
|
| MeSH Number(s) |
D03.383.742.680.245.500.950.500 D13.570.230.329.950.500 D13.570.230.500.925.500 D13.570.685.245.500.950.500
|
| Concept/Terms |
Lamivudine- Lamivudine
- 3TC
- 2',3'-Dideoxy-3'-thiacytidine
- 2',3' Dideoxy 3' thiacytidine
|
Below are MeSH descriptors whose meaning is more general than "Lamivudine".
Below are MeSH descriptors whose meaning is more specific than "Lamivudine".
This graph shows the total number of publications written about "Lamivudine" by people in this website by year, and whether "Lamivudine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 0 | 3 | 3 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 1 | 1 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 0 | 2 | 2 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2023 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Lamivudine" by people in Profiles.
-
Lartey M, Ganu VJ, Tachi K, Yang H, Anderson PL, Langaee T, Ojewale O, Boamah I, Obo-Akwa A, Antwi K, Bushman LR, Ellison L, Kwara A. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression. AIDS. 2024 03 01; 38(3):351-362.
-
Brooks KM, Kiser JJ, Ziemba L, Ward S, Rani Y, Cressey TR, Masheto GR, Cassim H, Deville JG, Ponatshego PL, Patel F, Aurpibul L, Barnabas SL, Mustich I, Coletti A, Heckman B, Krotje C, Lojacono M, Yin DE, Townley E, Moye J, Majji S, Acosta EP, Ryan K, Chandasana H, Brothers CH, Buchanan AM, Rabie H, Flynn PM. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. Lancet HIV. 2023 08; 10(8):e506-e517.
-
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 02 01; 92(2):153-161.
-
Erlandson KM, Fiorillo SP, Cardoso SW, Riviere C, Sanchez J, Hakim J, Kumarasamy N, Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation. AIDS Res Hum Retroviruses. 2017 Sep; 33(9):929-934.
-
Hu S, Neff CP, Kumar DM, Habu Y, Akkina SR, Seki T, Akkina R. A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy. Virology. 2017 01 15; 501:115-118.
-
Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ, Weinberg A. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015; 10(5):e0127062.
-
Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W, Infante R, Rana A, Kumarasamy N, Hakim J, Campbell TB. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015 May-Jun; 16(3):89-99.
-
Shivakoti R, Gupte N, Yang WT, Mwelase N, Kanyama C, Tang AM, Pillay S, Samaneka W, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Semba RD, Christian P, Campbell TB, Gupta A. Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy. Nutrients. 2014 Nov 13; 6(11):5061-78.
-
Erlandson KM, Gudza I, Fiorillo S, Ndemera B, Schooley RT, Gwanzura L, Borok M, Campbell TB. Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe. Int J Infect Dis. 2014 Jul; 24:6-10.
-
Nelson BC, Borok MZ, Mhlanga TO, Makadzange AT, Campbell TB. AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe. Int J Infect Dis. 2013 Oct; 17(10):e902-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|